Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on September 22, 2009
Japanese Journal of Clinical Oncology 2009 39(12):833-836; doi:10.1093/jjco/hyp110
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
39/12/833    most recent
hyp110v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Song, I. C.
Right arrow Articles by Lee, H. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, I. C.
Right arrow Articles by Lee, H. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment

Ik Chan Song1, Jae Sung Lim2, Hwan Jung Yun1, Samyong Kim1, Dae Young Kang3 and Hyo Jin Lee1

1 Department of Internal Medicine, Daejeon Regional Cancer Center, Chungnam National University Hospital
2 Department of Urology, Daejeon Regional Cancer Center, Chungnam National University Hospital
3 Department of Pathology, Daejeon Regional Cancer Center, Chungnam National University Hospital, Daejeon, Korea

For reprints and all correspondence: Hyo Jin Lee, Department of Internal Medicine, Chungnam National University Hospital, 640 Daesa-dong, Jung-gu, Daejeon, Korea. E-mail: cymed{at}cnuh.co.kr

Received February 16, 2009; accepted August 2, 2009

Sunitinib is a small molecular inhibitor of tyrosine kinases and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumour after disease progression or intolerance to imatinib therapy. Here, we describe biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma during sunitinib treatment. A 62-year-old man was referred to our hospital because of a mass in the scalp. He was diagnosed with left renal cell carcinoma with right renal and scalp metastases. In addition, synchronous prostate cancer involving less than one-half of the right lobe was found with a prostate-specific antigen (PSA) value of 23.4 ng/ml. Treatment was begun with sunitinib (50 mg daily, 4 weeks on and 2 weeks off). Regarding the prostate cancer, active monitoring was planned considering the far advanced renal cell carcinoma. Surprisingly, the PSA level was 3.4 ng/ml at week 6 and 0.2 ng/ml at week 12, and it subsequently remained normal. At the time of writing (cycle 6 of sunitinib therapy), the prostate nodule significantly decreased in size. Furthermore, a 12-core re-biopsy revealed pathological evidence of regression with sunitinib treatment, with control of his renal cell carcinoma.

Key Words: prostate cancer • sunitinib • treatment outcome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.